Santhera Pharmaceuticals Holding AG (XSWX:SANN) 14-Day RSI: 40.63 (As of Jul. 03, 2026)


XSWX:SANN Santhera Pharmaceuticals Holding AG XSWX:SANN
39 GF Score
Price CHF15.20
GF Value CHF23.24
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Santhera Pharmaceuticals Holding AG 14-Day RSI?

Santhera Pharmaceuticals Holding AG XSWX:SANN -0.26% 39 14-Day RSI is 40.63 as of Jul. 03, 2026. GuruFocus rates XSWX:SANN with a GF Score™ of 39/100 and a GF Value™ of CHF23.24 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,423 Biotechnology companies, Santhera Pharmaceuticals Holding AG ranks better than 76.81% on this metric.

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2026-07-03), Santhera Pharmaceuticals Holding AG's 14-Day RSI is 40.63.

The industry rank for Santhera Pharmaceuticals Holding AG's 14-Day RSI or its related term are showing as below:

XSWX:SANN's 14-Day RSI is ranked better than
76.81% of 1423 companies
in the Biotechnology industry
Industry Median: 49.99 vs XSWX:SANN: 40.63

Santhera Pharmaceuticals Holding AG  (XSWX:SANN) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Santhera Pharmaceuticals Holding AG 14-Day RSI Related Terms


XSWX:SANN vs VRTX, REGN, ALNY: 14-Day RSI Comparison

For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santhera Pharmaceuticals Holding AG 14-Day RSI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Santhera Pharmaceuticals Holding AG's 14-Day RSI falls into.


XSWX:SANN
39GF Score
Santhera Pharmaceuticals Holding AG XSWX:SANN
14-Day RSI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santhera Pharmaceuticals Holding AG  (XSWX:SANN) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 14-Day RSI →
What does a 14-Day RSI of 40.63 mean?
Santhera Pharmaceuticals Holding AG (XSWX:SANN) has a 14-Day RSI of 40.63 as of Jul. 03, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. According to the industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #330 out of 1423 companies in the Biotechnology industry, placing it in the top 23.2%.
Is Santhera Pharmaceuticals Holding AG's 14-Day RSI too high?
Santhera Pharmaceuticals Holding AG's current 14-Day RSI is 40.63. The Biotechnology industry median 14-Day RSI is 49.99. Santhera Pharmaceuticals Holding AG's value of 40.63 is 18.7% below this industry median. Based on the distribution chart, Santhera Pharmaceuticals Holding AG ranks #330 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Santhera Pharmaceuticals Holding AG has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Santhera Pharmaceuticals Holding AG's 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #330 out of 1423 companies for 14-Day RSI. This places Santhera Pharmaceuticals Holding AG in the top 23% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 49.99. Santhera Pharmaceuticals Holding AG's value of 40.63 is 18.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 49.99, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Santhera Pharmaceuticals Holding AG's current 14-Day RSI of 40.63 is 18.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. For the Biotechnology industry, the median 14-Day RSI is 49.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Santhera Pharmaceuticals Holding AG's current 14-Day RSI is 40.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santhera Pharmaceuticals Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG (XSWX:SANN) is currently considered Possible Value Trap. The stock's GF Value™ is CHF23.24, compared to a current price of CHF15.20 — trading 34.6% below its estimated fair value. The current 14-Day RSI is 40.63 and 18.7% below the Biotechnology industry median of 49.99. Santhera Pharmaceuticals Holding AG's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Santhera Pharmaceuticals Holding AG (XSWX:SANN), the current 14-Day RSI is 40.63 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santhera Pharmaceuticals Holding AG (XSWX:SANN) Overvalued in 2026?

Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued. The current stock price of CHF15.20 is trading 34.6% below its estimated GF Value™ of CHF23.24. GuruFocus considers Santhera Pharmaceuticals Holding AG to be Possible Value Trap.

Key valuation signals for XSWX:SANN:

  • 14-Day RSI: 40.63
  • GF Value™: CHF23.24 vs. price of CHF15.20 (34.6% below fair value)
  • GF Score™: 39/100 with 6 warning signs
  • Industry Position: 18.7% below the Biotechnology median (#330 of 1423)

No single metric tells the full story. See the XSWX:SANN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Santhera Pharmaceuticals Holding AG Business Description

Address Hohenrainstrasse 24, Pratteln, CHE, 4133
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
39GF Score

Get the complete analysis for XSWX:SANN

14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF15.20
Price
CHF23.24
GF Value